CLEC1B and COVID-19: This observation suggests that variation of amino acid residues in SARS‐CoV RBD contributes to the loss of CLEC2‐binding ability, and this can explain why severe immunothrombosis is reported in COVID‐19 patients, but is rarely found in SARS‐CoV‐infected victims.